House approves bill extending time for devicemakers to report defects: 3 takeaways

The Food and Drug Administration user fee reauthorization bill, which House representatives passed Wednesday, contains a measure that would triple the amount of time device companies have to report product issues, reports Star Tribune.

Advertisement

Here are three things to know.

1. If approved, the bill would give devicemakers 90 days, instead of 30, to report product malfunctions to the FDA. The legislation would also permit companies to summarize previous product malfunction reports, rather than filing detailed reports for each case.

2. The bill’s advocates say it will eliminate the repetitive process for reporting known product malfunctions, while critics believe the policy change could cause underreporting of malfunctions, which the FDA admits is already an issue.

3. The legislation would maintain a 30-day reporting period for device issues that directly cause patient injury.

More articles on supply chain:

7 must-reads for supply chain leaders this week
House passes FDA user fee reauthorization bill
Are outcomes-based drug contracts effective? 5 thoughts

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.